Ultimately, the PSMA3-AS1/miR-302a-3p/RAB22A pathway was validated to be related to the growth, invasion and migration of glioma, so it was considered as an underlying target in the diagnosis and treatment of glioma. Here, RAB22A is linked to glioma.